Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 Study of 4000 L-Scale Alglucosidase Alfa (Lumizyme) in Pompe Disease
2015-000512-18Phase 4
- Sponsor
- Sanofi
- Start
- Mar 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoint: Clinical stability or improvement at Week 52.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2015-000512-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000512-18.